Advertisement
IONS or LLY or PFE
Which Stock Would AI Choose? Ionis Pharmaceuticals (IONS) vs. Eli Lilly (LLY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- IONS shares have shown volatility in recent market activity, down over 12% in the past month amid broader biotech pressures, but up 130% over the past year on strong pipeline momentum including FDA priority review for olezarsen.
- LLY commands a premium valuation with blockbuster GLP-1 drugs Mounjaro and Zepbound driving 56% of 2025 revenues at $36.5 billion, though YTD performance lags at -8% due to sector rotation and pricing concerns.
- PFE offers value with a forward P/E around 9x and 6.4% dividend yield, posting YTD gains of 10% fueled by non-COVID growth in oncology and RSV vaccine Abrysvo, despite ongoing COVID sales decline.
- Relative performance highlights PFE's stability (beta 0.42) versus LLY's growth trajectory and IONS's high-beta biotech risk-reward profile.
- Market caps differ sharply: LLY at $885B dwarfs PFE's $154B and IONS's ~$10B, reflecting scale in pharma versus biotech innovation focus.
- Sentiment shifts favor growth in obesity/cardio-metabolic areas, positioning LLY strongly, while PFE and IONS emphasize pipeline diversification.
Introduction
This stock comparison examines IONS, LLY, and PFE, three pharma leaders navigating distinct challenges in the current market environment. IONS represents biotech innovation with RNA-targeted therapies, LLY dominates GLP-1 weight-loss and diabetes markets, and PFE leverages a diversified portfolio amid post-COVID transitions. Traders seeking momentum and growth may eye LLY's catalysts, while value-oriented investors could favor PFE's yield and stability. Biotech enthusiasts tracking relative performance and pipeline progress will find insights into sector exposure, valuation sensitivity, and market positioning relevant for informed decisions.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS), a leader in RNA-targeted therapeutics, focuses on rare diseases and neurology with a robust pipeline. Recent market activity has seen IONS shares decline over 12% in the past month and 9% over three months, trading around $74 amid broader biotech sector pressures. Despite this, the stock has surged 130% over the past year, reflecting optimism around commercial milestones. Key drivers include FDA priority review acceptance for olezarsen in severe hypertriglyceridemia, with potential launch in late 2026 and peak sales over $2 billion projected. TRYNGOLZA generated $108 million in 2025 net sales post-FCS approval, exceeding expectations, while DAWNZERA supports rare disease expansion. Q4 2025 revenues beat estimates at $203 million, up 34% annually, bolstering sentiment despite near-term volatility from clinical risks and execution in independent launches.
LLY Overview and Recent Performance
Eli Lilly (LLY), a global pharma giant, thrives on its GLP-1 portfolio addressing diabetes and obesity. In recent weeks, LLY shares have pulled back around 8% YTD and 5-8% monthly, trading near $990, pressured by sector rotations, pricing scrutiny, and competition in weight-loss drugs. Longer-term momentum remains strong, with 20% one-year gains driven by Mounjaro ($23 billion) and Zepbound ($13.5 billion) sales in 2025, comprising 56% of total revenues amid 43% Q4 growth to $19.3 billion. 2026 guidance projects $80-83 billion in revenue, fueled by supply expansions, international uptake, and Phase 3 successes. Positive analyst revisions and AI-enhanced R&D investments sustain bullish sentiment, though high valuations amplify sensitivity to demand shifts.
PFE Overview and Recent Performance
Pfizer (PFE), a diversified pharmaceutical powerhouse, balances legacy products with pipeline renewal post-COVID. Recent performance shows resilience, with shares up 10% YTD and 4.5% monthly around $27, outperforming peers amid value recovery. Non-COVID revenues grew 9% operationally in Q4 2025, led by Abrysvo RSV vaccine (up 136%), oncology biosimilars, Eliquis, and Prevnar, offsetting 40% COVID product declines to ~$6.5 billion annually. 2026 guidance anticipates $59.5-62.5 billion revenues, with 4% operational growth excluding COVID/LOE impacts, supported by cost realignments and ~20 pivotal trials. Sentiment benefits from 6.4% yield and low beta, though patent cliffs and R&D investments temper near-term gains.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top-performing AI trading bots from hundreds available, each employing machine-learning across thousands of tickers in stocks, ETFs, and crypto. Only those excelling in current market conditions—factoring volatility, momentum, and sector rotations—earn a spot in this dynamic section. Stats highlight impressive ranges: annualized returns up to +313%, win rates of 70-95%, and profit factors exceeding 3.0-12.5 across strategies like semiconductors (up to +227%, 70-80% wins), aerospace/defense (+121%, 74% wins), and volatility plays. Diverse timeframes (5-60 minutes) and styles suit scalpers, swing traders, and long-term investors. These bots deliver real-time signals with verified live performance, enabling copy trading. Explore Trending AI Robots to identify tools aligned with your risk profile and market outlook.
Head-to-Head Comparison
IONS, LLY, and PFE contrast sharply in business models: IONS' biotech focus on RNA therapies targets rare diseases with high-risk/high-reward catalysts like olezarsen launches, versus LLY's scaled GLP-1 dominance in massive obesity/diabetes markets and PFE's broad portfolio spanning vaccines, oncology, and cardio. Growth drivers favor LLY's 25%+ revenue trajectory from blockbusters, while IONS eyes $4B+ peak from pipeline and PFE targets 4% ex-COVID growth via biosimilars and obesity entries. Recent momentum tilts to PFE's YTD outperformance, but LLY leads stability trade-offs. Risks include IONS' execution in commercial shift, LLY's competition/pricing, and PFE's LOE cliffs. All share cardio-metabolic exposure, but valuations differ: PFE at 9x forward P/E offers value, LLY 43x growth premium, and IONS negative due to losses. Sentiment leans growth for LLY, income for PFE.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward LLY in this comparison, citing superior trend consistency from GLP-1 momentum, robust 2026 revenue guidance, and dominant market positioning in high-growth obesity therapeutics. While IONS offers pipeline upside and PFE provides stability and yield, LLY's catalysts exhibit stronger probabilistic near-term outperformance relative to peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IONS’s FA Score shows that 0 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s), and PFE’s FA Score reflects 1 green FA rating(s).
- IONS’s FA Score: 0 green, 5 red.
- LLY’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IONS’s TA Score shows that 4 TA indicator(s) are bullish while LLY’s TA Score has 5 bullish TA indicator(s), and PFE’s TA Score reflects 4 bullish TA indicator(s).
- IONS’s TA Score: 4 bullish, 4 bearish.
- LLY’s TA Score: 5 bullish, 3 bearish.
- PFE’s TA Score: 4 bullish, 4 bearish.
Price Growth
IONS (@Biotechnology) experienced а +0.72% price change this week, while LLY (@Pharmaceuticals: Major) price change was -1.32% , and PFE (@Pharmaceuticals: Major) price fluctuated +2.38% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
Reported Earning Dates
IONS is expected to report earnings on Apr 29, 2026.
LLY is expected to report earnings on Apr 30, 2026.
PFE is expected to report earnings on May 05, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| IONS | LLY | PFE | |
| Capitalization | 12.5B | 828B | 157B |
| EBITDA | -273.12M | 31.7B | 16.8B |
| Gain YTD | -4.298 | -13.595 | 12.537 |
| P/E Ratio | N/A | 40.39 | 20.26 |
| Revenue | 944M | 65.2B | 62.6B |
| Total Cash | 2.68B | 7.27B | 13.6B |
| Total Debt | 2.07B | 42.5B | 64B |
IONS | LLY | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 67 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 62 Fair valued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 62 | 20 | 100 | |
SMR RATING 1..100 | 98 | 13 | 74 | |
PRICE GROWTH RATING 1..100 | 41 | 55 | 27 | |
P/E GROWTH RATING 1..100 | 74 | 94 | 34 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (34) in the Pharmaceuticals Major industry is in the same range as LLY (62) in the Pharmaceuticals Major industry, and is significantly better than the same rating for IONS (100) in the Biotechnology industry. This means that PFE's stock grew similarly to LLY’s and significantly faster than IONS’s over the last 12 months.
LLY's Profit vs Risk Rating (20) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (62) in the Biotechnology industry, and is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that LLY's stock grew somewhat faster than IONS’s and significantly faster than PFE’s over the last 12 months.
LLY's SMR Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (74) in the Pharmaceuticals Major industry, and is significantly better than the same rating for IONS (98) in the Biotechnology industry. This means that LLY's stock grew somewhat faster than PFE’s and significantly faster than IONS’s over the last 12 months.
PFE's Price Growth Rating (27) in the Pharmaceuticals Major industry is in the same range as IONS (41) in the Biotechnology industry, and is in the same range as LLY (55) in the Pharmaceuticals Major industry. This means that PFE's stock grew similarly to IONS’s and similarly to LLY’s over the last 12 months.
PFE's P/E Growth Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (74) in the Biotechnology industry, and is somewhat better than the same rating for LLY (94) in the Pharmaceuticals Major industry. This means that PFE's stock grew somewhat faster than IONS’s and somewhat faster than LLY’s over the last 12 months.
| IONS | LLY | PFE | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 80% | 3 days ago 74% | N/A |
| Stochastic ODDS (%) | 3 days ago 75% | 3 days ago 70% | 3 days ago 66% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 61% | 3 days ago 51% |
| MACD ODDS (%) | 3 days ago 73% | 3 days ago 67% | 3 days ago 55% |
| TrendWeek ODDS (%) | 3 days ago 71% | 3 days ago 59% | 3 days ago 55% |
| TrendMonth ODDS (%) | 3 days ago 74% | 3 days ago 57% | 3 days ago 51% |
| Advances ODDS (%) | 5 days ago 66% | 11 days ago 71% | 3 days ago 56% |
| Declines ODDS (%) | 7 days ago 65% | 4 days ago 55% | 10 days ago 57% |
| BollingerBands ODDS (%) | 3 days ago 67% | 3 days ago 81% | 3 days ago 52% |
| Aroon ODDS (%) | 3 days ago 74% | 3 days ago 57% | 3 days ago 52% |
Advertisement
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with AZN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then AZN could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with MRK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then MRK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +1.25% | ||
| MRK - PFE | 66% Loosely correlated | +3.13% | ||
| BMY - PFE | 64% Loosely correlated | +2.05% | ||
| BIIB - PFE | 61% Loosely correlated | +0.76% | ||
| AMGN - PFE | 58% Loosely correlated | +1.69% | ||
| NVS - PFE | 54% Loosely correlated | +1.50% | ||
More | ||||